Pathogenicity of novel hantavirus isolate and antigenicity and immunogenicity of novel strain-based inactivated vaccine.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam, The Netherlands : Elsevier Science
      Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
    • Subject Terms:
      Orthohantavirus* ; Hemorrhagic Fever with Renal Syndrome*/prevention & control ; Hemorrhagic Fever with Renal Syndrome*/epidemiology ; Hantavirus Infections*/prevention & control ; Hantaan virus* ; Communicable Diseases*; Mice ; Animals ; Virulence ; Vaccines, Inactivated ; CD8-Positive T-Lymphocytes ; Antibodies, Viral
    • Abstract:
      Background: Hantaan virus (HTNV, Orthohantavirus hantanensae species, Hantaviridae family) is the main etiological agent responsible for hemorrhagic fever with renal syndrome (HFRS). The novel HTNV may pose a potential danger to the control and prevention of HFRS in China, which highlights the importance of vaccine development in public health management. In previous studies, our laboratory discovered and successfully isolated a new HTNV strain, HV004 strain, from Apodemus agrarius captured in an epidemic area in Hubei, China.
      Methods: An initial biological and pathogenicity characterization of HTNV 76-118 (standard train), HV114 strain (a clinical isolate from Hubei province in 1986), and the novel isolate HV004 strain from the epidemic areas of Hubei province were performed in susceptible cells and in vivo. An experimental HV004 strain inactivated vaccine was prepared, and its corresponding immunogenicity was analyzed in BALB/c mice.
      Results: HV004 strain had a similar but higher pathogenicity than HTNV 76-118 and HV114 in suckling mice. A subcutaneous vaccination (s.c.) with the inactivated HTNV vaccine adjuvanted with aluminum, followed by a challenge intraperitoneally with 10 6  FFU/ml HTNV, afforded full protection against an HTNV challenge. All immunized mice in every group elicited serum neutralizing antibodies with increasing dosages, which may protect mice from HTNV infection. A dose-dependent stimulation index of splenocytes was also observed in immunized mice. The percentage of IFN-γ-producing CD3 + CD8 + T cells was significantly higher in the spleens of immunized mice than in those of control mice.
      Conclusions: These findings suggest that the inactivated HTNV vaccine may stimulate mice to produce high levels of antibodies with neutralization activity and elicit specific anti-HTNV humoral and cellular immune responses in BALB/c mice against the prevalent strain of HTNV in south central China.
      Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2023 Elsevier Ltd. All rights reserved.)
    • Contributed Indexing:
      Keywords: HFRS; Immunity; Orthohantavirus hantanense (HTNV); Pathogenicity; Vaccine
    • Accession Number:
      0 (Vaccines, Inactivated)
      0 (Antibodies, Viral)
    • Publication Date:
      Date Created: 20231112 Date Completed: 20231128 Latest Revision: 20231128
    • Publication Date:
      20240829
    • Accession Number:
      10.1016/j.vaccine.2023.11.017
    • Accession Number:
      37953099